Trending...
- Yet another EU country´s Data Protection Authority makes it official! Google Analytics is out!
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Yatsen Holding Limited with Losses of $100,000 to Contact the Firm
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Barclays PLC with Losses of $100,000 to Contact the Firm
WEST HOLLYWOOD, Calif. - Californer -- Simufilam is a leading candidate to become the first effective treatment for Alzheimer's Disease. In an analysis by sfbanc financial, Cassava Sciences, Inc. (SAVA) was upgraded as a Strong Buy, from 8/10 to 9.5/10.
The drug in development purportedly works by retiring the proper conformation of filamin A, a molecule involved in the cascade of Alzheimer's disease. Open-label results are showing effectiveness in 84% of subjects treated. These promising results, along with recent insider buying, has led the sfbanc community to upgrade the stock.
More on The Californer
Additional results from the open label trial are expected by the end of this year. Call volume shows optimism for the results of the Cognitive Maintenance Study (CMS) in late 2023. This trial will include 100 subjects randomized to switch from active drug to placebo. Simufilam is currently in two randomized placebo-controlled Phase 3 trials.
sfbanc is a financial community that provides analysis and discussion of available public information in the finance sector. https://sfbanc.com
The drug in development purportedly works by retiring the proper conformation of filamin A, a molecule involved in the cascade of Alzheimer's disease. Open-label results are showing effectiveness in 84% of subjects treated. These promising results, along with recent insider buying, has led the sfbanc community to upgrade the stock.
More on The Californer
- Sydney Brachytherapy Group is the first private non-melanoma skin cancer clinic in Sydney to offer OncoBeta's Rhenium-SCT
- PermaTherm Announces Panels Delivered Quickly Program
- General Inception Creates First-Ever "Igniter" for New Company Formation
- ASI Hosts 24th Annual iNNOVATIONS Conference and Announces Award Winners
- NuVasive Announces Agenda for Investor Day 2022
Additional results from the open label trial are expected by the end of this year. Call volume shows optimism for the results of the Cognitive Maintenance Study (CMS) in late 2023. This trial will include 100 subjects randomized to switch from active drug to placebo. Simufilam is currently in two randomized placebo-controlled Phase 3 trials.
sfbanc is a financial community that provides analysis and discussion of available public information in the finance sector. https://sfbanc.com
Source: sfbanc
Filed Under: Biotech
1 Comment
- J Hautau:
SAVA🚀 no side effects. Promising.
Latest on The Californer
- Disney+ Original Series 'Genius: MLK/X' From National Geographic Sets Ensemble Cast
- California Is Making It Cheaper to Replace Your Lawn to Save Water and Save Money
- CHIRLA, IMMIGRANT RIGHTS GROUPS MOBILIZE IN SUPPORT OF U.S. SENATOR PADILLA'S BILL TO EXPAND A PATHWAY FOR RESIDENCY FOR MILLIONS OF LONG-TERM RESIDENTS
- California: Alongside Farmworkers at the State Capitol, Governor Newsom Signs Law Expanding Farmworker Union Rights
- San Jose: Public Review Draft MND: Silver Creek and Capitol Chick-fil-A Project
- Warner Bros. Discovery, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Warner Bros. Discovery, Inc. (WBD)
- Sensoria Health & Defender announce availability of first smart diabetic boot with remote patient monitoring
- Hundreds Walk For Recovery, Jobs A Solution
- The World's First Stuttering Mentalist - Johnathan Smith Is A Story Of Determination And Hard Work
- Corporate Leaders, PGA Tour Winners, and HR Luminaries Highlight Make Work Better Summit
- California to Build More Housing, Faster
- Water Reclamation Facility in Moorpark informing future drought resilience
- Asian Hall of Fame Announces Induction 2022
- State Gives $130 Million Boost to Projects Essential to Reliabilty of Southern California's Water Supply
- Distroller Donates Neonate Babies to NICU Families for NICU Sibling Support Day on Sept. 29
- California: On the Record with Governor Gavin Newsom: Saving Water & Building a More Resilient Future
- ATEN Technology Renovates the Desktop for the Hybrid Work Challenge with New KVM Switch
- Experienced Intellectual Property Attorney Christopher Franich Joins Snell & Wilmer's SD Office
- Triunfo Water & Sanitation District Board Approves Reducing Sprinkler Irrigation Time
- Edge AI Innovator Femtosense Raises $8 Million Series A Funding